DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
This is a prospective, non-interventional, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
• Adults aged 18 years or older
• Diagnosis of ILD by traditional or HRCT determined by the site/institution that conducted the HRCT
• Patients with connective tissue disease must have a baseline forced vital capacity of \<70%
• RHC confirmed PH (mean pulmonary artery pressure \>20 mmHg, pulmonary arterial wedge pressure ≤15 mmHg, pulmonary vascular resistance \>2 WU).
• For patients to be eligible for Cohort 1, they must not be receiving inhaled treprostinil at Baseline.
• For patients to be eligible for Cohort 2, they must have initiated Tyvaso/Tyvaso DPI at 1 of the following time points:
‣ Baseline
⁃ ≤60 days prior to Baseline
• For patients to be eligible for Cohort 3, they must be receiving Tyvaso/Tyvaso DPI at Baseline and for \>60 days prior to Baseline
• Co-enrollment in other observational or interventional studies is permitted
• Patient is willing and able to provide informed consent and complete surveys/questionnaires in English or Spanish